/ 33 Shares
06-May-2024 - 08-May-2024
₹ 430 - ₹ 452
₹ 14916.00
33
40,470,342
Face Value - ₹ 2/- Per Share
Listing at NSE BSE
429,230 Application Required in Retail for 1 Time.
Registrar : Link Intime India Private Ltd
Fresh Issue of Equity Shares aggregating upto Rs. 760 Cr and Offer for Sale of upto 23,932,732 Equity Shares
Category | % | Shares/Amount |
---|---|---|
QIB | 50% | 20,235,170 Shares Rs. 914.63 Cr |
HNI 1 | 5% | 2,023,518 Shares Rs. 91.46 Cr @ 4380 Form 1X |
HNI 2 | 10% | 4,047,034 Shares Rs. 640.24 Cr @ 8760 Form 1X |
Retail | 35% | 14,164,620 Shares Rs. 621.81 Cr @ 429231 Form 1X |
BRLMs: Kotak Mahindra Capital, Citigroup Global, J.P.Morgan, Nomura Financial
Retail (Upto 2 Lakh) | HNI (2 Lakh to 10 Lakh) | HNI (Above 10 Lakh) |
---|---|---|
429231 Form 1X | 4380 Form 1X | 8760 Form 1X |
Category | Lots | Shares | Amount |
---|---|---|---|
Retail (Upto 2 Lakh) | 1 | 33 | ₹ 14,916 |
Retail (Upto 2 Lakh) | 13 | 429 | ₹ 193,908 |
S-HNI (2 Lakh to 10 Lakh) | 14 | 462 | ₹ 208,824 |
S-HNI (2 Lakh to 10 Lakh) | 67 | 2211 | ₹ 999,372 |
B-HNI (Above 10 Lakh) | 68 | 2244 | ₹ 1,014,288 |
09-May-2024 06:05
Category | Book Size | Subscription | No. of Times |
---|---|---|---|
QIB | 8,094,068 ₹ 365.85 Cr. | 656,665,251 ₹ 29681.27 Cr. | 81.13x |
HNI (<10 LAKH) | 2,023,518 ₹ 91.46 Cr. | 40,684,611 ₹ 1838.94 Cr. | 20.11x |
HNI2 (>10 LAKH) | 4,047,034 ₹ 182.93 Cr. | 101,768,997 ₹ 4599.96 Cr. | 25.15x |
RETAIL | 14,164,620 ₹ 640.24 Cr. | 57,434,817 ₹ 2596.05 Cr. | 4.05x |
Total | 28,329,240 | 856,553,676 | 30.24x |
Category | Book Size | Subscription | No. of Times |
---|---|---|---|
QIB | 8,094,068 ₹ 365.85 Cr. | 656,665,251 ₹ 29681.27 Cr. | 81.13x |
HNI (<10 LAKH) | 2,023,518 ₹ 91.46 Cr. | 40,684,611 ₹ 1838.94 Cr. | 20.11x |
HNI2 (>10 LAKH) | 4,047,034 ₹ 182.93 Cr. | 101,768,997 ₹ 4599.96 Cr. | 25.15x |
RETAIL | 14,164,620 ₹ 640.24 Cr. | 57,434,817 ₹ 2596.05 Cr. | 4.05x |
Total | 28,329,240 | 856,553,676 | 30.24x |
*Excluding Anchor
Total No. of Application Approx : ~1282161 (2.99 Appwise)
Disclaimer: The above-mentioned information / data are sourced from the websites of National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) and are subject to change on real time basis. For updated information / data you can visit their respective website. The information / data provided herein above are for information purpose only and provided "AS IS" and "AS AVAILABLE" basis and without warranty, express or implied. We do not guarantee or warrant the accuracy, adequacy or completeness of the information received through the said websites. “We” hold not responsibility of any kind as regard to any discrepancies, errors, omissions, losses or damages. “We” including its affiliates and any of its officers, directors, personnel and employees, shall not liable for any loss, damage of any nature, including but not limited to direct, indirect, punitive, special, exemplary, consequential, as also any loss of profit in any way arising from the use of information / data received through the said websites. The recipient alone shall be fully responsible / are liable for any decision taken on the basis of such information / data. All recipients should before acting upon the said information make their own investigation, seek appropriate professional advice.
Incorporated on October 16, 1998, Indegene is a Provider of digital-led commercialization services for the life sciences industry, including biopharmaceutical, emerging biotech and medical devices companies and the sales and marketing of their products. Their solutions enable life sciences companies to develop products, launch them in the market, and drive sales through their life cycle in a more effective, efficient and modern manner. The company achieves this by combining over 2 decades of healthcare domain expertise and fit-for-purpose technology. Their portfolio of solutions covers all aspects of commercial, medical, regulatory, and R&D operations of life sciences companies.
Company’s Enterprise Commercial Solutions and Omnichannel Activation solutions cater to the commercial functions of life sciences companies while their Enterprise Medical Solutions and Enterprise Clinical Solutions cater to their medical and R&D functions. Enterprise Commercial Solutions primarily involve assisting life sciences companies with their digital marketing operations.
The company also provides digital asset management, marketing automation, customer data management and analytics solutions to measure the effectiveness of marketing campaigns.
Omnichannel Activation solutions help life sciences companies leverage a “digital first” approach for optimizing the last-mile promotion of biopharmaceutical products and medical devices to healthcare professionals HCPs across multiple channels.
Under the Enterprise Medical Solutions, indigene establishes Centres of Excellence (“CoEs”) to consolidate large scale regulatory and medical operations for their clients.
Indegene also offers Enterprise Clinical Solutions and consultancy services. Their Enterprise Clinical Solutions help drive efficiencies in the drug discovery and clinical trial operations of life sciences companies. They provide consultancy services through their subsidiary, DT Associates Ltd, under the “DT Consulting” brand.
Indegene has established client relationships with each of the 20 largest biopharmaceutical companies in the world by revenue for the FY2023, having earned more than 69% of their total revenue from continuing operations for each of the FY2023, FY2022 and FY2021 from these 20 customers.
Since their inception, Indegene has completed a total of 13 acquisitions, and enjoyed synergistic benefits from each of these acquisitions.
As of December 31, 2023, Indegene had 65 active clients whom they deliver solutions from their operation hubs located across North America, Europe, and Asia.
Business Strategies
Strengthen the “go to market” engine;
Develop the technology portfolio;
Pursue strategic acquisitions;
Focus on operational excellence
Krishnamurthy Venugopala Tenneti is a Non-Executive Independent Director on the Board of the company. Dr. Ashish Gupta is a Non-Executive Independent Director on the Board of the company. Jairaj Manohar Purandare is a Non-Executive Independent Director on the Board of the company. Pravin Udhyavara Bhadya Rao is a Non-Executive Independent Director on the Board of the company. Georgia Nikolakopoulou Papathomas is a Non-Executive Independent Director on the Board of the company. Manish Gupta
Indegene Limited's revenue increased by 39.85% and profit after tax (PAT) rose by 63.43% between the financial year ending with March 31, 2023 and March 31, 2022.
Period Ended | 31 Dec 2023 | 31 Mar 2023 | 31 Mar 2022 | 31 Mar 2021 |
Assets | 2,518.15 | 2,203.87 | 1,353.47 | 596.04 |
Revenue | 1,969.75 | 2,364.10 | 1,690.50 | 996.92 |
Profit After Tax | 241.90 | 266.10 | 162.82 | 149.41 |
Net Worth | 1,327.00 | 1,063.72 | 763.90 | 324.51 |
Reserves and Surplus | 1,282.65 | 1,019.43 | 763.55 | 324.19 |
Total Borrowing | 399.33 | 394.34 | 18.24 | 24.76 |
Amount in ? Crore |
The Company proposes to utilise the Net Proceeds towards funding the following objects:
Once you create your account, Login to Us.
Under IPO Section, you will be able to see a list of Ongoing IPOs, where you can click on apply button.
Add quantity of shares to apply – Maximum 3 bids are allowed (For retail category – max amount Rs.2,00,000/-).
Enter your UPI ID and you will receive mandate on your UPI App.
Once you accept the mandate, Application is submitted successful.